A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM)

Objectives: Infliximab (IFX) is widely used in patients with refractory Takayasu arteritis (TAK). Recently, the IFX-biosimilar CT-P13 has been introduced for the treatment of inflammatory diseases. The aim of this study was to assess the efficacy and safety of CT-P13 in patients with refractory TAK....

Descripción completa

Detalles Bibliográficos
Autores principales: Campochiaro, Corrado, Tomelleri, Alessandro, Sartorelli, Silvia, Sembenini, Camilla, Papa, Maurizio, Fallanca, Federico, Picchio, Maria, Cavalli, Giulio, De Cobelli, Francesco, Baldissera, Elena, Dagna, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502860/
https://www.ncbi.nlm.nih.gov/pubmed/34646844
http://dx.doi.org/10.3389/fmed.2021.723506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502860/
https://www.ncbi.nlm.nih.gov/pubmed/34646844
http://dx.doi.org/10.3389/fmed.2021.723506

Ejemplares similares